Estamos realizando la búsqueda. Por favor, espere...

Gb3/cd77 is a predictive marker and promising therapeutic target for head and neck cancer

Abstract: Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.

 Autoría: García-Hevia L., Muñoz-Guerra D., Casafont Í., Morales-Angulo C., Ovejero V.J., Lobo D., Fanarraga M.L.,

 Fuente: Biomedicines 2022, 10(4), 732

 Editorial: MDPI AG

 Año de publicación: 2022

 Nº de páginas: 12

 Tipo de publicación: Artículo de Revista

 DOI: 10.3390/biomedicines10040732

 ISSN: 2227-9059

 Proyecto español: MAT2016- 81955-REDT

 Url de la publicación: https://doi.org/10.3390/biomedicines10040732